Erectile dysfunction (ED) is the persistent difficulty achieving or maintaining an erection sufficient for satisfactory sexual activity. ED can range from a complete inability to achieve an erection to more subtle changes in firmness, fullness, duration, or consistency.
Erectile dysfunction is extremely common and becomes more prevalent with age. Research suggests ED affects approximately 40% of men by age 40, more than half of men between ages 40 and 70, and up to 70% of men over age 70. However, ED is not an inevitable consequence of healthy aging and may indicate underlying vascular, metabolic, hormonal, neurologic, or psychological factors that warrant evaluation.
Erectile dysfunction is often multifactorial rather than the result of a single problem. Common contributors include impaired vascular and endothelial function, cardiovascular disease, diabetes and insulin resistance, obesity, testosterone deficiency or other hormonal disorders, certain medications, neurologic conditions, psychological factors, and lifestyle factors such as sleep, exercise, tobacco use, and alcohol consumption.
ED becomes more common with age, but it should not simply be dismissed as a normal or unavoidable part of getting older. Age-related changes in vascular function, hormones, metabolism, medications, and overall health can all affect erectile function - and many of these factors can be identified and treated.
Yes. Erectile function depends heavily on healthy blood vessels and endothelial function. Because the penile arteries are smaller than the coronary arteries, vascular dysfunction may become apparent in erections before cardiovascular disease produces other symptoms. ED can therefore be an important opportunity to evaluate cardiovascular and metabolic risk rather than treating it solely as a sexual symptom.
Low testosterone can contribute to erectile dysfunction, although it is not the cause of ED in every man. Testosterone influences libido, nitric oxide signaling, penile tissue health, sexual arousal, and orgasmic function. When testosterone deficiency is suspected, laboratory evaluation can help determine whether hormonal health is contributing to the problem.
Testosterone replacement therapy is not a universal treatment for ED and is most appropriate when a clinically meaningful testosterone deficiency has been identified. Learn more on our Testosterone Replacement Therapy page.
Yes. Certain antidepressants, blood pressure medications, and other prescription medications can contribute to erectile or sexual dysfunction. A thorough ED evaluation should include a review of current medications and, when appropriate, consideration of alternatives in coordination with the prescribing clinician.
For many men, PDE5 inhibitors such as Viagra® (sildenafil) and Cialis® (tadalafil) are highly effective and remain first-line medical treatments for ED. However, these medications improve the erectile response rather than correcting every potential cause of erectile dysfunction.
When ED reflects vascular disease, metabolic dysfunction, testosterone deficiency, medication effects, or multiple contributing factors, addressing those issues alongside medication may provide a more complete treatment strategy.
A thorough ED evaluation considers much more than erectile symptoms alone. Depending on the individual, evaluation may include cardiovascular risk and blood pressure, metabolic health and blood sugar regulation, testosterone and other hormones, thyroid function, medications, lifestyle factors, psychological health, and other medical conditions that can affect sexual function.
The objective is to identify the factors contributing to ED so treatment can be appropriately individualized.
Treatment depends on the type, severity, and underlying contributors to ED. Options may include lifestyle and cardiovascular risk modification, treatment of metabolic or hormonal abnormalities, PDE5 inhibitors such as sildenafil (Viagra®) or tadalafil (Cialis®), intracavernosal injections, vacuum erection devices, and selected advanced therapies including low-intensity shockwave therapy, PRP (P-Shot®), and therapeutic Botox®. Severe ED that does not respond to nonsurgical treatment may ultimately be treated with a penile implant.
An inadequate response to oral ED medication does not mean there are no other options. The first step is often determining why the medication is not producing the desired response and whether vascular, hormonal, metabolic, neurologic, medication-related, or other factors are contributing.
Depending on the findings, additional options may include dose or medication adjustments, intracavernosal injections, vacuum erection devices, shockwave therapy, PRP, therapeutic Botox®, or combination treatment.
In some men, yes. Improving cardiovascular fitness, metabolic health, weight, blood pressure, sleep, nutrition, and tobacco or alcohol exposure may improve erectile function, particularly when these factors are contributing to vascular or metabolic dysfunction.
Non-pharmacologic treatments such as vacuum erection devices and low-intensity shockwave therapy may also be considered in appropriately selected patients.
Low-intensity shockwave therapy (LiSWT) is a non-invasive treatment that uses low-energy acoustic waves to stimulate biologic changes within penile tissue. Research suggests it may improve endothelial function, vascular signaling, and blood flow, particularly in men with mild to moderate vasculogenic ED.
LiSWT is considered investigational for erectile dysfunction by the American Urological Association and is not FDA-approved specifically for ED.
The P-Shot® uses platelet-rich plasma (PRP) prepared from a patient's own blood. Concentrated platelets and growth factors are injected into targeted areas of penile tissue with the goal of supporting tissue repair, vascular remodeling, and erectile function.
Research on PRP for ED continues to evolve, and the treatment is considered investigational. It may be used independently or alongside other therapies such as low-intensity shockwave therapy in appropriately selected patients.
Botulinum toxin (Botox®) is an emerging treatment being studied for erectile dysfunction, particularly in men who have had an inadequate response to conventional therapies. It is thought to work by relaxing smooth muscle within the penis, which may facilitate blood flow and improve erectile response.
Therapeutic Botox® remains investigational and is not considered a first-line ED treatment, but it may be considered for carefully selected patients.
Yes. Male sexual dysfunction extends beyond erectile function and may include low libido, difficulty with arousal or orgasm, premature ejaculation, and other changes in sexual performance or satisfaction. Evaluation is individualized because hormonal, vascular, neurologic, medication-related, physical, and psychological factors can overlap.
Schedule a consultation with the Performance Men's Health team.